JAK inhibitors in lichen planus: a review of pathogenesis and treatments
Lichen planus (LP) is an auto-inflammatory skin disorder identified by a presence of T-cell lymphocytes at the dermal-epidermal junction. It is hypothesized that the INF–γ/CXCL10 axis fulfills a major role in the onset and persistence of chronic inflammation in LP. Since Janus kinases (JAKs) are inv...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2022-11-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/09546634.2022.2116926 |
| _version_ | 1797683452224471040 |
|---|---|
| author | Ali Motamed-Sanaye Yasaman Fatemeh Khazaee Motahareh Shokrgozar Maryam Alishahi Najmeh Ahramiyanpour Maliheh Amani |
| author_facet | Ali Motamed-Sanaye Yasaman Fatemeh Khazaee Motahareh Shokrgozar Maryam Alishahi Najmeh Ahramiyanpour Maliheh Amani |
| author_sort | Ali Motamed-Sanaye |
| collection | DOAJ |
| description | Lichen planus (LP) is an auto-inflammatory skin disorder identified by a presence of T-cell lymphocytes at the dermal-epidermal junction. It is hypothesized that the INF–γ/CXCL10 axis fulfills a major role in the onset and persistence of chronic inflammation in LP. Since Janus kinases (JAKs) are involved in the transduction of INF–γ signals, they may be good targets for LP treatment. Several case reports and case series described the safety and efficacy of upadacitinib (2 articles), tofacitinib (6 articles), baricitinib (4 articles), and Ruxolitinib (1 Article) in the treatment of LP variants. The predominant variants that JAK inhibitors improved were lichen planopilaris, nail LP, and erosive LP. Considering the role of the JAK pathway in LP pathogenesis and the evidence provided by these reports, it seems JAK inhibitors would be effective therapeutic agents for LP treatment. Hence, these agents should be trialed and evaluated further. |
| first_indexed | 2024-03-12T00:15:38Z |
| format | Article |
| id | doaj.art-0f2b906a477e4887bb872dd70be1c455 |
| institution | Directory Open Access Journal |
| issn | 0954-6634 1471-1753 |
| language | English |
| last_indexed | 2024-03-12T00:15:38Z |
| publishDate | 2022-11-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj.art-0f2b906a477e4887bb872dd70be1c4552023-09-15T14:28:52ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532022-11-013383098310310.1080/09546634.2022.21169262116926JAK inhibitors in lichen planus: a review of pathogenesis and treatmentsAli Motamed-Sanaye0Yasaman Fatemeh Khazaee1Motahareh Shokrgozar2Maryam Alishahi3Najmeh Ahramiyanpour4Maliheh Amani5Infectious Diseases Research Center, student research committee, Faculty of Medicine, Gonabad University of Medical SciencesDepartment of Pediatrics, Faculty of Medicine, Gonabad University of Medical SciencesFaculty of Medicine, Gonabad University of Medical SciencesFaculty of Medicine, Gonabad University of Medical SciencesDepartment of Dermatology, Afzalipour Hospital, Afzalipour Faculty of Medicine, Kerman University of Medical SciencesDepartment of Dermatology, Faculty of Medicine, Gonabad University of Medical SciencesLichen planus (LP) is an auto-inflammatory skin disorder identified by a presence of T-cell lymphocytes at the dermal-epidermal junction. It is hypothesized that the INF–γ/CXCL10 axis fulfills a major role in the onset and persistence of chronic inflammation in LP. Since Janus kinases (JAKs) are involved in the transduction of INF–γ signals, they may be good targets for LP treatment. Several case reports and case series described the safety and efficacy of upadacitinib (2 articles), tofacitinib (6 articles), baricitinib (4 articles), and Ruxolitinib (1 Article) in the treatment of LP variants. The predominant variants that JAK inhibitors improved were lichen planopilaris, nail LP, and erosive LP. Considering the role of the JAK pathway in LP pathogenesis and the evidence provided by these reports, it seems JAK inhibitors would be effective therapeutic agents for LP treatment. Hence, these agents should be trialed and evaluated further.http://dx.doi.org/10.1080/09546634.2022.2116926lichen planusjak inhibitorsjak pathwaytofacitinibbarcitinibupadacitinibruxolitinib |
| spellingShingle | Ali Motamed-Sanaye Yasaman Fatemeh Khazaee Motahareh Shokrgozar Maryam Alishahi Najmeh Ahramiyanpour Maliheh Amani JAK inhibitors in lichen planus: a review of pathogenesis and treatments Journal of Dermatological Treatment lichen planus jak inhibitors jak pathway tofacitinib barcitinib upadacitinib ruxolitinib |
| title | JAK inhibitors in lichen planus: a review of pathogenesis and treatments |
| title_full | JAK inhibitors in lichen planus: a review of pathogenesis and treatments |
| title_fullStr | JAK inhibitors in lichen planus: a review of pathogenesis and treatments |
| title_full_unstemmed | JAK inhibitors in lichen planus: a review of pathogenesis and treatments |
| title_short | JAK inhibitors in lichen planus: a review of pathogenesis and treatments |
| title_sort | jak inhibitors in lichen planus a review of pathogenesis and treatments |
| topic | lichen planus jak inhibitors jak pathway tofacitinib barcitinib upadacitinib ruxolitinib |
| url | http://dx.doi.org/10.1080/09546634.2022.2116926 |
| work_keys_str_mv | AT alimotamedsanaye jakinhibitorsinlichenplanusareviewofpathogenesisandtreatments AT yasamanfatemehkhazaee jakinhibitorsinlichenplanusareviewofpathogenesisandtreatments AT motaharehshokrgozar jakinhibitorsinlichenplanusareviewofpathogenesisandtreatments AT maryamalishahi jakinhibitorsinlichenplanusareviewofpathogenesisandtreatments AT najmehahramiyanpour jakinhibitorsinlichenplanusareviewofpathogenesisandtreatments AT malihehamani jakinhibitorsinlichenplanusareviewofpathogenesisandtreatments |